U.S. Markets close in 1 hr, 7 mins
| Symbol | Value | Change | Percentage Change |
|---|---|---|---|
| DJIA | 11,401.55 | -230.83 | -1.98% |
| NASDAQ | 2,292.03 | -33.85 | -1.46% |
| S&P 500 | 1,258.64 | -23.55 | -1.84% |
| Day Low 10:13 AM EDT | 5.23 | |
|---|---|---|
| Day High 09:30 AM EDT | 5.40 |
|
| Range | 0.17 | |
| Volume | 177,673 | |
| 30-Day Avg. Vol. | 614,000 |
|
| Difference | -71.06% | |
| Market Cap. | 252.53 M | |
| Change | 1.88 M | |
| Shares Out. | 47.2 M | |
| Percent Traded | 0.38% | |
| Revenue | 86.24 M | |
| Earnings | -4.28 M | |
| EPS (TTM) | 0.08 |
| 52-Wk Low 1/4/08 | 3.45 | |
|---|---|---|
| 52-Wk High 9/27/07 | 6.36 |
|
| Range | 2.91 | |
| Prev. Close 7/23/08 | 5.31 | |
| Today's Open | 5.40 | |
| Change | 1.69% | |
| Dividend (TTM) | 0.00 | |
| Div. Yield (TTM) | 0.00% |
|
| Beta | 1.3408 | |
| P/E Ratio (TTM) | 33.44 | |
| P/E Ratio (Fwd.) | -6.00 |
NPS Pharmaceuticals' calcium receptor technology is the launching point for its development of treatments for hyperparathyroidism (HPT) and osteoporosis. The company worked with Amgen and the pharmaceutical ... View Full Description
| Earnings/Share(EPS) | Estimate | Actual | Difference |
|---|---|---|---|
| 2 Quarters Ago | 0.28 12/31/07 | -0.13 12/31/07 |
-0.41
Missed
|
| Last Quarter | -0.125 3/31/08 | -0.28 3/31/08 |
-0.155
Missed
|
| Quarterly - 03/31/2008 | Annual - 2007 | |
|---|---|---|
| Total Revenue | 25.18 M | 86.25 M |
| Gross Profit | 20.54 M | 73.86 M |
| Operating Income | 4.81 M | 8.14 M |
| Net Income | -13.09 M | -4.28 M |
Real-Time Quote
